NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago
Conditions: Atopic Dermatitis, Eczema
Interventions: Crisaborole
Countries: United States
The purpose of this study is to develop biomarkers to predict what medication is best for each child with atopic dermatitis (eczema). Participants will come in to Lurie Children's Allergy of Dermatology clinic for a skin examination and complete surveys. They will apply Eucrisa medication to their skin for 28 days before returning for a second and final skin examination and complete surveys. During these skin exams, tape will be placed on the skin and removed to collect skin cell samples. Photos will also be taken of the skin where tape was placed. There is an optional blood draw.
Sex: ALL
Age: 4 Months to 17 Years
Healthy volunteers: No
Study type: INTERVENTIONAL
Inclusion Criteria: * AD diagnosis by dermatologist or allergist based on Hanifin and Rajka criteria * 5% or more treatable body surface area involvement * baseline Investigator's Static Assessment (ISGA) score of mild (2) or moderate (3) * patient on stable regimens (consistent use 14 days before day 1 of enrollment) of inhaled corticosteroids and antihistamines * must have lesional skin in the antecubital fossa Exclusion Criteria: * use of topical corticosteroid, calcineurin inhibitor, or PDE4 inhibitor within 14 days of enrollment * significant active infection * any previous use of biologic therapy * no pruritus at baseline visit, or other pruritic condition * washing/moisturizer use 24 hours prior to tape strip biomarker collection at site * uncontrolled asthma, uncontrolled allergic rhinitis, or other sleep disturbing condition
- Chicago, Illinois, United States